Antithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in Turkey: Inferences from GARFIELD-AF registry

Basit Öğe Kaydı
dc.authoridSucu, Murat/0000-0002-3695-5461
dc.authoridozdemir, kurtulus/0000-0001-9152-304X
dc.authoridALTUN, ARMAGAN/0000-0002-3233-8263
dc.authoridYilmaz, Mehmet Birhan/0000-0002-8169-8628
dc.authoridErsanli, Murat Kazim/0000-0003-1847-3087
dc.authoridSahiner, Mehmet Levent/0000-0002-0985-3144
dc.contributor.authorSayin, Begum Yetis
dc.contributor.authorOkutucu, Sercan
dc.contributor.authorYilmaz, Mehmet Birhan
dc.contributor.authorOzdemir, Kurtulus
dc.contributor.authorAydinlar, Ali
dc.contributor.authorSahin, Durmus Yildiray
dc.contributor.authorAltun, Armagan
dc.date.accessioned2024-10-26T18:00:04Z
dc.date.available2024-10-26T18:00:04Z
dc.date.issued2019
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractObjective: The corner stone of atrial fibrillation therapy includes the prevention of stroke with less adverse effects. The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) study provided data to compare treatment strategies in Turkey with other populations and every-day practice of stroke prevention management with complications. Methods: GARFIELD-AF is a large-scale registry that enrolled 52,014 patients in five sequential cohorts at > 1.000 centers in 35 countries. This study was initiated to track the evolution of global anticoagulation practice, and to study the impact of NOAC therapy in AF. A total of 756 patients from 17 enrolling sites in Turkey were in cohort 4 and 5. Treatment strategies at diagnosis initiated by CHA(2)DS(2)-VASc score, baseline characteristics of patients, treatment according to stroke and bleeding risk profiles, and INR values were analyzed in cohorts. Additionally, event rates during the first year follow up were evaluated. Results: AF patients in Turkey were mostly seen in young women. Stroke risk according to the CHADS(2) score and CHA(2)DS(2)-VASc score compared with world data. The mean of risk score values, including HAS-BLED score were lower in Turkey than in the world data. The percentage of patients receiving FXa inhibitor with or without an antiplatelet usage was more than the other drug groups. All-cause mortality was higher in Turkey. Different form world data when HAS-BLED score was above 3, the therapy was mostly changed to antiplatelet drugs in Turkey. Conclusion: In addition to deficiencies in available treatment options, patient care and clinical outcomes of patients with AF, the data of GARFIELD-AF provide data from Turkey about therapeutic strategies and best practices.
dc.identifier.doi10.14744/AnatolJCardiol.2019.78178
dc.identifier.endpage280
dc.identifier.issn2149-2263
dc.identifier.issn2149-2271
dc.identifier.issue5
dc.identifier.pmid31062761
dc.identifier.scopus2-s2.0-85065650573
dc.identifier.scopusqualityQ3
dc.identifier.startpage272
dc.identifier.trdizinid342733
dc.identifier.urihttps://doi.org/10.14744/AnatolJCardiol.2019.78178
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/342733
dc.identifier.urihttps://hdl.handle.net/20.500.12418/27510
dc.identifier.volume21
dc.identifier.wosWOS:000468584800007
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherTurkish Soc Cardiology
dc.relation.ispartofAnatolian Journal of Cardiology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectatrial fibrillation
dc.subjectanticoagulation
dc.subjectstroke
dc.titleAntithrombotic treatment patterns and stroke prevention in patients with atrial fibrillation in Turkey: Inferences from GARFIELD-AF registry
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu